Table 2.
Characteristics of rheumatoid arthritis (RA) and undifferentiated arthritis (UA) patients at baseline within the early inflammatory arthritis (EIA) cohort
| RA at baseline (n = 14) | UA at baseline (n = 6) | |
|---|---|---|
| Female sex n (%) | 10 (71) | 5 (83) |
| Age (years) | 56 ± 12 | 40 ± 13* |
| Symptom duration (months) | 10 ± 6 | 12 ± 8 |
| Rheumatoid factor titre | 38 (16, 147) | 13·5 (10, 165) |
| Anti-CCP titre (n = 9) | 52 (1, 340)† | 2 (2, 2·7) |
| Tender joint count | 16·5 (12·5, 19·3) | 12 (4·5, 23·75) |
| Swollen joint count | 2·0 (0·0, 6·5) | 2·0 (0·0, 6·5) |
| Assessor global score | 48 (35, 61) | 49 (37, 62) |
| ESR | 28 (13, 46) | 14 (4, 22)* |
| DAS28 | 5·5 (4·7, 6·8) | 4·6 (3·3, 6·0) |
| C-reactive protein | 4 (4, 23) | 4 (4, 128) |
| Modified HAQ | 0·94 (0·35, 1·56) | 0·82 (0·43, 1·69) |
| Larsen score | 2 (0, 2) | 0 (0, 0·5)* |
| EQ-5D total | 0·62 (0·40, 0·74) | 0·69 (0·44, 0·80) |
Patients in the EIA cohort were classified as either UA or RA based on fulfilment of the 1987 American College of Rheumatology (ACR) criteria for RA. Values are presented as mean ± standard deviation or median (interquartile values).
*
P < 0·05 versus RA at baseline.
†
Anti-cyclic citrullinated peptide (CCP) titre was not available for all patients at baseline. DAS28: disease activity score 28; ESR: erythrocyte sedimentation rate; HAQ: health assessment questionnaire.